CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6321 result(s)

triheptanoin (TBC)

Last Updated: February 26, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: triheptanoin
Indications: Triheptanoin is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).

  • Brand Name: TBC
  • Manufacturer: Ultragenyx Canada Inc
  • Project Number: SR0684-000
  • Project Status: Pending
  • Submission Type: Initial

tucatinib (Tukysa )

Last Updated: February 26, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: tucatinib
Indications: ​Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.

  • Brand Name: Tukysa
  • Manufacturer: Seagen Canada Inc.
  • Project Number: PC0243-000
  • Project Status: Pending
  • Submission Type: Initial

apomorphine hydrochloride (Kynmobi)

Last Updated: February 26, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: apomorphine hydrochloride
Indications: ​Indicated for the acute, intermittent treatment of “OFF” episodes in patients with Parkinson's disease.

  • Brand Name: Kynmobi
  • Manufacturer: Sunovion Pharmaceuticals Canada Inc.
  • Project Number: SR0650-000
  • Project Status: Active
  • Submission Type: Initial

nintedanib (Ofev)

Last Updated: February 26, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: nintedanib
Indications: Treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD)

  • Brand Name: Ofev
  • Manufacturer: Boehringer Ingelheim (Canada) Ltd.
  • Project Number: SR0654-000
  • Project Status: Active
  • Submission Type: Initial

von Willebrand Factor [recombinant] (Vonvendi)

Last Updated: February 25, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: von Willebrand Factor [recombinant]
Indications: ​Indicated for: Treatment and Control of bleeding episodes in adults (age ≥18) diagnosed with von Willebrand Disease (VWD).Perioperative management of bleeding in adults (age ≥18) diagnosed with VWD

  • Brand Name: Vonvendi
  • Manufacturer: Shire Pharma Canada ULC, now part of Takeda
  • Project Number: ST0639-000
  • Project Status: Active
  • Submission Type: Initial

romosozumab (Evenity )

Last Updated: February 25, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: romosozumab
Indications: The treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.

  • Brand Name: Evenity
  • Manufacturer: Amgen Canada Inc.
  • Project Number: SR0676-000
  • Project Status: Active
  • Submission Type: Initial

ofatumumab (Kesimpta)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: ofatumumab
Indications: For the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.

  • Brand Name: Kesimpta
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0657-000
  • Project Status: Active
  • Submission Type: Initial

CADTH Pharmaceutical Reviews Update — Issue 21

Last Updated: February 25, 2021
Result type: Reports
Product Line: Pharmaceutical Review Update

See Pharmaceutical Reviews Update – Issue 21 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include:

  • Update for Patients and Communities
  • Revised target dates for pERC meetings
  • Revised timelines for posting clinician group input

risperidone (Perseris )

Last Updated: February 25, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: risperidone
Indications: ​Treatment of schizophrenia in adults.

  • Brand Name: Perseris
  • Manufacturer: HLS Therapeutics Inc.
  • Project Number: SR0671-000
  • Project Status: Active
  • Submission Type: Initial